AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake (EI)
Number of subjects: 227
Study 31318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat intake
Number of subjects: 227
Study 31318492 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed sleep timing midpoint
Number of subjects: 227
Study 27927048 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 10 mcg/h
Number of subjects: 110
Study 27927048 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 40 mcg/h
Number of subjects: 110
Study 27927048 — intervention group
Group type: EXPERIMENTAL
Intervention: BTDS 80 mcg/h
Number of subjects: 110
Study 27927048 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin (400 mg)
Number of subjects: 110
Study 27927048 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone with BTDS
Number of subjects: 110
Study 27927048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 25210019 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted albendazole therapy (n = 467)
Number of subjects: 980
Study 25210019 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontargeted albendazole therapy (n = 513)
Number of subjects: 980
Study 25210019 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole therapy (both targeted and nontargeted)
Number of subjects: 980
Study 23471702 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of amlodipine, telmisartan, and hydrochlorothiazide
Number of subjects: 0
Study 23471702 — intervention group
Group type: COMPARATOR
Intervention: Individual marketed products (reference)
Number of subjects: 0
Study 21315132 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed partial dentures
Number of subjects: 500
Study 21315132 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable partial dentures
Number of subjects: 500
Study 21315132 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete dentures
Number of subjects: 500
Study 20090396 — intervention group
Group type: EXPERIMENTAL
Intervention: MM+CPB
Number of subjects: 65
Study 20090396 — intervention group
Group type: EXPERIMENTAL
Intervention: MM+TS
Number of subjects: 65
Study 20090396 — intervention group
Group type: COMPARATOR
Intervention: MM
Number of subjects: 65
Study 17923069 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical score assessment
Number of subjects: 110
Study 15477698 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98
Study 15477698 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98
Study 15477698 — intervention group
Group type: COMPARATOR
Intervention: Stretching (sham) exercises
Number of subjects: 98
Study 11354573 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin (280 mg in pump prime)
Number of subjects: 21
Study 11354573 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21
Study 9112303 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization (group A)
Number of subjects: 145
Study 9112303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit up and take 20 deep breaths on 10 occasions daily (group B)
Number of subjects: 145
Study 9112303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit up and blow bubbles in a bottle containing 10 cm water through a plastic tube 20 times on 10 occasions daily (group C)
Number of subjects: 145
Study 8200556 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (tropisetron)
Number of subjects: 7
Study 8200556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 3322828 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin marker in capsules of gemfibrozil (4.4 micrograms twice a day)
Number of subjects: 0
Study 3322828 — intervention group
Group type: COMPARATOR
Intervention: Digoxin marker in capsules of placebo (4.4 micrograms twice a day)
Number of subjects: 0
Study 31537375 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilute betadine (0.02% solution) added to sterile water (SW) splash basin
Number of subjects: 104
Study 31537375 — intervention group
Group type: COMPARATOR
Intervention: Standard sterile water (SW) splash basin
Number of subjects: 104
Study 29112090 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear liquid diet
Number of subjects: 184
Study 29112090 — intervention group
Group type: COMPARATOR
Intervention: Low-fibre diet
Number of subjects: 184
Study 28801440 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (baseline study, no intervention implemented)
Number of subjects: 372
Study 24758736 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen 40 mg
Number of subjects: 12
Study 24758736 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 24270300 — intervention group
Group type: EXPERIMENTAL
Intervention: Job-specific WHS
Number of subjects: 176
Study 24270300 — intervention group
Group type: COMPARATOR
Intervention: Generic WHS (Control)
Number of subjects: 176
Study 21575102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg·kg(‐1)
Number of subjects: 160
Study 21575102 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg·kg(‐1)
Number of subjects: 160
Study 21575102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 μg·kg(‐1)
Number of subjects: 160
Study 21575102 — intervention group
Group type: COMPARATOR
Intervention: Control group (acetaminophen as needed)
Number of subjects: 160
Study 18470742 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple channel exposure therapy (M-CET)
Number of subjects: 0
Study 16782927 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin and cisplatin (CC)
Number of subjects: 109
Study 16782927 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin + fluorouracil + vincristine (C5V)
Number of subjects: 109
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported family history of cancer in males
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported family history of cancer in females
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported family history of cancer by gender
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported family history of cancer by ethnicity
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported family history of cancer by age
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Commonly reported cancers in families
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported cancer rates to expected cancer rates
Number of subjects: 150000
Study 12727673 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported:expected ratios for specific cancers
Number of subjects: 150000
Study 10739358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 60 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70
Study 10739358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate 90 mg i.v. every 3 weeks for a maximum of six cycles
Number of subjects: 70
Study 10739358 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate treatment
Number of subjects: 70
Study 10739358 — intervention group
Group type: COMPARATOR
Intervention: Terminal care in hospital (last 3 months before death)
Number of subjects: 70
Study 10739358 — intervention group
Group type: COMPARATOR
Intervention: Average monthly direct costs during treatment phase
Number of subjects: 70
Study 10739358 — intervention group
Group type: COMPARATOR
Intervention: Average monthly direct costs during follow-up
Number of subjects: 70
Study 10739358 — intervention group
Group type: COMPARATOR
Intervention: In-patient costs
Number of subjects: 70
Study 9176830 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 g/day DHA
Number of subjects: 0
Study 9176830 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 g/day DHA
Number of subjects: 0
Study 9176830 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vegetable oil)
Number of subjects: 0
Study 1412606 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of 200 mg of labetalol
Number of subjects: 16
Study 1412606 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of 0.5 mg/kg of labetalol
Number of subjects: 16
Study 3926731 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 litre of 20 per cent Intralipid
Number of subjects: 12
Study 3926731 — intervention group
Group type: COMPARATOR
Intervention: Physiological saline
Number of subjects: 12
Study 30861510 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal suppositories containing low‐molecular‐weight hyaluronic acid (HA) from day 1 of radiotherapy for 5 weeks.
Number of subjects: 180
Study 30861510 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 180
Study 29956364 — intervention group
Group type: EXPERIMENTAL
Intervention: Chocolate cookies (cookie group)
Number of subjects: 118
Study 29956364 — intervention group
Group type: COMPARATOR
Intervention: Control group (no cookies)
Number of subjects: 118
Study 26972955 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet therapy plus pravastatin
Number of subjects: 3170
Study 26972955 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy alone
Number of subjects: 3170
Study 25227834 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM) intervention
Number of subjects: 184
Study 25227834 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of HBM and Theory of Planned Behavior (TPB) constructs intervention
Number of subjects: 184
Study 25227834 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 184
Study 22490761 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tailored lifestyle advice and personal counselling
Number of subjects: 340
Study 22490761 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 340
Study 20942575 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (combination of antioxidants extracted from fruit, berries, and vegetables) for 12 weeks
Number of subjects: 40
Study 20942575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 40
Study 17541115 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 0
Study 17541115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15653210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 94
Study 15653210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 12122521 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy
Number of subjects: 60
Study 12122521 — intervention group
Group type: COMPARATOR
Intervention: Sham physiotherapy
Number of subjects: 60
Study 10357412 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with monitoring using [technetium 99m]-sestamibi (MIBI) scintimammography
Number of subjects: 32
Study 10357412 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapy imaging using [technetium 99m]-sestamibi (MIBI) scintimammography
Number of subjects: 32
Study 7497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermic CPB (n = 19, rectal temperature: 35.9 ± 0.1 degrees C)
Number of subjects: 38
Study 7497759 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic CPB (n = 19, rectal temperature: 29.2 ± 0.5 degrees C)
Number of subjects: 38
Study 7497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Normothermic and Hypothermic)
Number of subjects: 38
Study 7497759 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak plasma elastase levels
Number of subjects: 38
Study 2149508 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin (Zoladex) 3.6 mg depot preparation combined with flutamide (Eulexin) 250 mg t.i.d.
Number of subjects: 327
Study 2149508 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy
Number of subjects: 327
Study 6997516 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 2-g dose of metronidazole
Number of subjects: 176
Study 6997516 — intervention group
Group type: COMPARATOR
Intervention: Seven-day regimen of metronidazole (250 mg three times daily)
Number of subjects: 176
Study 30356229 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality‐based training
Number of subjects: 54
Study 30356229 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 54
Study 26164807 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese group (BMI ≥ 30 kg/m²)
Number of subjects: 771
Study 26164807 — intervention group
Group type: COMPARATOR
Intervention: Nonobese group (BMI 23.4 ± 2.6 kg/m²)
Number of subjects: 771
Study 24173773 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF-I/rhIGFBP-3 complex
Number of subjects: 56
Study 24173773 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22126349 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride chewing gum (FCG: 50 μg fluoride)
Number of subjects: 45
Study 22126349 — intervention group
Group type: COMPARATOR
Intervention: Placebo gum
Number of subjects: 45
Study 18174269 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 1.2 g/day for 2 days
Number of subjects: 54
Study 18174269 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc (Zn) 60 mg/day for 1 day
Number of subjects: 54
Study 18174269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 17023703 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with native phytate (40 g/d)
Number of subjects: 55
Study 17023703 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein with native isoflavones
Number of subjects: 55
Study 17023703 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline BMI
Number of subjects: 55
Study 17023703 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 55
Study 17023703 — intervention group
Group type: EXPERIMENTAL
Intervention: LDL cholesterol and BMI
Number of subjects: 55
Study 12389880 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone follow-up (48-72 hours after discharge)
Number of subjects: 150
Study 12389880 — intervention group
Group type: COMPARATOR
Intervention: Control group (no telephone follow-up)
Number of subjects: 150
Study 12389880 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up group (telephone follow-up)
Number of subjects: 150
Study 9822499 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily aspirin (60 mg)
Number of subjects: 2539
Study 9822499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2539
Study 7859450 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple clips for tubal occlusion
Number of subjects: 510
Study 7859450 — intervention group
Group type: COMPARATOR
Intervention: Single clip for tubal occlusion
Number of subjects: 510
Study 2698360 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabeculectomy at diagnosis followed by supplementary medical therapy if necessary
Number of subjects: 116
Study 2698360 — intervention group
Group type: COMPARATOR
Intervention: Conventional management of medical therapy followed by trabeculectomy in unsuccessful cases
Number of subjects: 116
Study 4876730 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic trial treatment
Number of subjects: 0
Study 4876730 — intervention group
Group type: COMPARATOR
Intervention: Earlier trial treatment in Morocco
Number of subjects: 0
Study 395128 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine
Number of subjects: 0
Study 395128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide
Number of subjects: 0
Study 395128 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31369613 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control (low‐dose exercise) and manual therapy
Number of subjects: 40
Study 31369613 — intervention group
Group type: EXPERIMENTAL
Intervention: General strength and conditioning training (moderate‐dose exercise)
Number of subjects: 40
Study 29190852 — intervention group
Group type: COMPARATOR
Intervention: Traditional Circuit Resistance Training (TCRT)
Number of subjects: 44
Study 29190852 — intervention group
Group type: COMPARATOR
Intervention: Instability Circuit Resistance Training (ICRT)
Number of subjects: 44
Study 29190852 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 44
Study 26637987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination at 6 months
Number of subjects: 183
Study 26637987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination at 12 months
Number of subjects: 183
Study 26637987 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis A vaccination at 15 months
Number of subjects: 183
Study 26637987 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 183
Study 24703415 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg breakfast (EB)
Number of subjects: 20
Study 24703415 — intervention group
Group type: COMPARATOR
Intervention: Cereal breakfast (CB)
Number of subjects: 20
Study 23063375 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 50 mg once daily
Number of subjects: 120
Study 23063375 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 100 mg once daily
Number of subjects: 120
Study 23063375 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 200 mg once daily
Number of subjects: 120
Study 23063375 — intervention group
Group type: COMPARATOR
Intervention: Mirabegron 300 mg once daily
Number of subjects: 120
Study 23063375 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron (various doses)
Number of subjects: 120
Study 19916246 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid (soybean oil, medium‐chain triglycerides, olive and fish oil)
Number of subjects: 44
Study 19916246 — intervention group
Group type: COMPARATOR
Intervention: Lipid emulsion based on olive and soybean oil (Control)
Number of subjects: 44
Study 17786128 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Drug Monitoring (TDM)
Number of subjects: 190
Study 17786128 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 190
Study 17786128 — intervention group
Group type: EXPERIMENTAL
Intervention: TDM-directed dose modifications
Number of subjects: 190
Study 14681839 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (3 mg copper/d as copper-glycinate) for 6 weeks
Number of subjects: 38
Study 14681839 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper supplementation (3 mg copper/d as copper-glycinate) plus zinc supplementation (30 mg zinc/d as zinc-glycinate) for 6 weeks
Number of subjects: 38
Study 14681839 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 38
Study 12077738 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30
Number of subjects: 50
Study 12077738 — intervention group
Group type: COMPARATOR
Intervention: BHI 30(t=0)
Number of subjects: 50
Study 12077738 — intervention group
Group type: COMPARATOR
Intervention: BHI 30(t=-30)
Number of subjects: 50
Study 9449404 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium 40 mmol, Calcium 30 mmol (1200 mg), Magnesium 14 mmol (336 mg)
Number of subjects: 300
Study 9449404 — intervention group
Group type: COMPARATOR
Intervention: Calcium 30 mmol (1200 mg)
Number of subjects: 300
Study 9449404 — intervention group
Group type: COMPARATOR
Intervention: Magnesium 14 mmol (336 mg)
Number of subjects: 300
Study 9449404 — intervention group
Group type: COMPARATOR
Intervention: Potassium, Calcium, and Magnesium together
Number of subjects: 300
Study 7616978 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine sulfate (1.9 mg/mL) plus droperidol (0.125 mg/mL)
Number of subjects: 40
Study 7616978 — intervention group
Group type: COMPARATOR
Intervention: Morphine sulfate (2 mg/mL)
Number of subjects: 40
Study 2374275 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (1.5 g three times daily)
Number of subjects: 13
Study 605762 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 microgram/kg i.v. naloxone
Number of subjects: 100
Study 605762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microgram/kg i.v. naloxone
Number of subjects: 100
Study 605762 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 microgram/kg i.m. naloxone
Number of subjects: 100
Study 605762 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 microgram/kg i.m. naloxone
Number of subjects: 100
Study 605762 — intervention group
Group type: COMPARATOR
Intervention: Control (no naloxone)
Number of subjects: 100
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 8 weeks
Number of subjects: 468
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 8 weeks
Number of subjects: 468
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 2 weeks
Number of subjects: 468
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 2 weeks
Number of subjects: 468
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 4 weeks
Number of subjects: 468
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 4 weeks
Number of subjects: 468
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 2 weeks (baseline LA grade C/D)
Number of subjects: 468
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 2 weeks (baseline LA grade C/D)
Number of subjects: 468
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 4 weeks (baseline LA grade C/D)
Number of subjects: 468
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 4 weeks (baseline LA grade C/D)
Number of subjects: 468
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan 20 mg once daily for 8 weeks (baseline LA grade C/D)
Number of subjects: 468
Study 31409606 — intervention group
Group type: COMPARATOR
Intervention: lansoprazole 30 mg once daily for 8 weeks (baseline LA grade C/D)
Number of subjects: 468
Study 31409606 — intervention group
Group type: EXPERIMENTAL
Intervention: vonoprazan
Number of subjects: 468